Literature DB >> 1663926

Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.

L J Piddock1, M C Hall, R N Walters.   

Abstract

The NCTC type strains of Escherichia coli, Enterobacter cloacae, Serratia marcescens and Klebsiella pneumoniae were exposed to 3, 5 and 10 x MIC of nalidixic acid, enoxacin, ciprofloxacin, PD 117596 and PD 127391. From each strain a mutant with a high MIC of quinolones alone (gyrA) and a mutant with intermediate resistance to quinolones, some beta-lactams, chloramphenicol and tetracycline (multiply resistant, m-r) were selected on agar containing antibiotics. The gyrA mutants required a higher concentration of quinolone to inhibit DNA synthesis by 50% but quinolone uptake kinetics and outer membrane profile were the same as the wild type. The m-r mutants had similar DNA synthesis IC50 as the wild type, decreased quinolone uptake kinetics and had decreased expression of an OMP of approximately 40 kD. The gyrA and m-r mutants were then exposed to 3, 5 and 10 x MIC of the same quinolones and new mutants (F2) selected. The F2 mutants from the gyrA mutants displayed a further increase in quinolone MIC; the F2 mutants from the m-r mutants had several phenotypes: high quinolone MICs with cross resistance to other agents, high quinolone resistance alone, or intermediate quinolone resistance alone. Most F2 mutants had MICs above the recommended breakpoint concentrations for quinolones. The F2 mutants often had altered biochemical profiles (API 20E), however, only in the case of E. cloacae did this affect speciation with the strains being identified as Rhanella aquatalis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663926     DOI: 10.1093/jac/28.2.185

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

3.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.

Authors:  L J Piddock; D J Griggs; M C Hall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 5.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.

Authors:  L J Piddock; A J Marshall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 9.  Mechanisms of quinolone resistance.

Authors:  B Wiedemann; P Heisig
Journal:  Infection       Date:  1994       Impact factor: 3.553

10.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.